Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine
Authors:
- Luciana CondeLCLuciana Conde
- Valter MonteiroVMValter Monteiro
- Joao C.R. FreitasJFJoao C.R. Freitas
- Jameson CrandellJCJameson Crandell
- Lauren LawresLLLauren Lawres
- Fernanda TanaFTFernanda Tana
- Mallery I. BrebanMBMallery I. Breban
- Fahima AktherFahima Akther
- Jordan PolsterJPJordan Polster
- Abigail PorzucekAPAbigail Porzucek
- Tauyne M. RamiroTRTauyne M. Ramiro
- 2 September 2026
- journal article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
Abstract
Dengue causes over 390 million annual infections globally. Qdenga (TAK-003), the only widely available dengue vaccine, has an incompletely defined immunological profile. We performed longitudinal immunological profiling of 110 adults from a dengue-endemic region, including older adults (≥65 years), to assess the effects of immune imprinting and vaccine design on humoral and cellular immunity. Qdenga elicited B and T cell activation across groups but generated serostatus-dependent, serotype-skewed antibody responses. Only 8% of DENV-naïve individuals developed tetravalent neutralizing responses, whereas one-third responded to a single serotype, predominantly DENV-2, the vaccine backbone. DENV-exposed individuals mounted broader responses shaped by preexisting immunity, yet DENV-4 neutralization remained consistently poor. Neutralizing antibody titers plateaued after the first dose, with no increase following the second. These findings clarify why balanced tetravalent immunity is rarely achieved with Qdenga and demonstrate that both immune imprinting and vaccine backbone limit the breadth and magnitude of the responses. This has important implications for deployment, long-term protection in naive populations, and DENV-4–targeted boosters.Keywords
Funding Information
- Stavros Niarchos Foundation
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (P01AI106695)
- National Institutes of Health (R21AI197057)
- Duke Claude D. Pepper Older Americans Independence Center, Duke Aging Center, Duke University (P30AG021342)
- National Institute of Science and Technology in Dengue and Host-Pathogens Interactions (408527/2024-2)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (444164/2024/3)
This publication has 47 references indexed in Scilit:
- Anti-dengue virus antibodies that elicit complement-mediated lysis of Zika virion correlate with protection from severe dengue diseaseCell Reports, 2025
- Distinct features of a peripheral T helper subset that drives the B cell response in dengue virus infectionCell Reports, 2025
- Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trialThe Lancet Global Health, 2024
- The MegaPool Approach to Characterize Adaptive CD4+ and CD8+ T Cell ResponsesCurrent Protocols, 2023
- Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adultsVaccine, 2023
- Humoral and cellular immune memory to four COVID-19 vaccinesCell, 2022
- Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trialThe Lancet Infectious Diseases, 2020
- Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2020
- Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trialThe Lancet, 2020
- Antibody response to influenza vaccination in the elderly: A quantitative reviewVaccine, 2006